Related Experiment Video

Updated: May 9, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Community-acquired pneumonia: 2012 history, mythology, and science

Gerald R Donowitz1

  • 1GRD@VIRGINIA.EDU

Transactions of the American Clinical and Climatological Association
|July 23, 2013
PubMed

Insights

Community-acquired pneumonia (CAP) is a significant cause of illness and death. Clinical decisions for CAP treatment involve a mix of science and practice, offering insights into medical decision-making.

Area of Science:

  • Infectious Diseases
  • Clinical Medicine
  • Medical Practice

Background:

  • Pneumonia is a major cause of morbidity and mortality globally.
  • It disproportionately affects the elderly, being a leading cause of death in those over 65.
  • Community-acquired pneumonia (CAP) presents ongoing therapeutic challenges for physicians.

Observation:

  • Key clinical questions persist regarding CAP management, including antibiotic initiation and cessation.
  • Decisions on patient selection for treatment and choice of antimicrobial agents remain complex.
  • Historical practices, anecdotal evidence, and scientific data often inform CAP treatment strategies.

Findings:

  • The therapeutic approach to CAP is influenced by a blend of established science and evolving evidence.
  • Clinical decision-making in CAP management reflects a dynamic interplay between different knowledge sources.
  • Understanding these decision-making processes provides a model for other medical problem areas.

Implications:

  • Improved understanding of CAP treatment decisions can refine clinical practice guidelines.
  • This model can illuminate how clinical practice is established across various medical fields.
  • Evidence-based medicine plays a crucial role in optimizing patient outcomes for pneumonia.

More Related Videos

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia04:32

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia

Published on: June 28, 2018

A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice07:43

A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice

Published on: September 28, 2016

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: